INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Medical University of Silesia
Katowice, PoloniaPublicaciones en colaboración con investigadores/as de Medical University of Silesia (14)
2024
-
Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study
JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387
2023
-
Percutaneous paravalvular leak closure after transcatheter aortic valve implantation: the international PLUGinTAVI Registry
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 19, Núm. 5, pp. e442-e449
2022
-
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414
-
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
American Journal of Hematology
-
The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study
European Respiratory Journal, Vol. 60, Núm. 3
2021
-
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718
-
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Journal of Hematology and Oncology
-
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
American Journal of Hematology, Vol. 96, Núm. 9, pp. 1120-1130
2020
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
-
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
British Journal of Haematology, Vol. 189, Núm. 1, pp. 84-96
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
2017
-
Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380